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BACKGROUND
Brain arteriovenous malformations (bAVMs) are abnormal shunts that bypass the capillary bed and directly divert blood from the arterial to the venous circulation, without
exchanging nutrients or dissipating the arterial blood pressure. They are thought to
be congenital vascular lesions that occur during the late stages of fetal development,
however the exact pathogenesis has not been elucidated yet.1 History of hemorrhage,
small AVM size, high arterial feeding blood pressure, and deep venous drainage are the
main risk factors that increase the likelihood of AVM rupture. According to the American
Stroke Association, 1 in 200-500 people have an AVM, while 25% of AVM patients experience seizures and 50% of patients suffer intracranial hemorrhage (ICH) at some point
in their lives. 2 Also, 5-15% of AVM patients experience severe headaches because of the
increased intracranial pressure and a similar percentage of patients exhibit neurological
deficits.1 With the advent of noninvasive imaging, AVMs are being detected at an early,
unruptured stage, but the optimal course of action for preventing future complications still remains uncertain. The ARUBA trial strove to determine whether medical
management or interventional therapy has a better long-term outcome for patients
with unruptured AVMs. While it provides important data, limitations in its study design
raise doubts concerning the generalizability of its findings.
The study planned to include 800 patients who were to be followed for a minimum
of five and a maximum of seven years. 3 They were randomly assigned to one of two
groups, the interventional therapy and medical management group. Patients in the
medical management group received only pharmacological therapy for the medical
symptoms that they experienced (unless they developed hemorrhage or infarction,
in which case they were switched into the other group). Patients in the interventional
therapy group received endovascular surgery, microsurgery, or radiosurgery, with or
without pharmacological therapy depending on their concurrent medical conditions.
The primary hypothesis was that medical management is more effective in the treatment of patients with unruptured bAVMs, the primary endpoint was death or stroke,
the secondary endpoint was the quality of life, while the functional outcome status was
measured using the Rankin scale. 3
Previous studies had shown that early interventional treatment in patients with ruptured
bAVMs is necessary and patients did not have major future clinical problems.3 Interventional therapy includes endovascular surgery, which aims to occlude the nidus by
delivering liquid embolics or embolic coils via a catheter, microsurgical resection of the
AVM, or radiosurgery that induces a vascular injury response resulting in AVM obliteration
within 1 or 2 years.1 A multimodal therapy that involves more than one of these interventional procedures can also be performed on certain patients. Furthermore, medical
management was shown to be very effective in treating unruptured bAVMs as indicated
by the very low rate of future hemorrhage. Yet, based on data from the Columbia University Medical Center, interventional treatment of ruptured AVMs had a significantly greater
likelihood of hemorrhage and/or clinical impairment (Rankin score ≥2) than medical
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management of unruptured AVMs. It is
thus imperative to compare the effectiveness of the two methods of treatment
only on patients with unruptured bAVMs,
since patients who present with an ICH
have an already much higher risk of
experiencing a subsequent ICH (hazard
ratio of 3.6).4 The ARUBA trial is the first
study comparing medical management to
surgical care on patients with unruptured
bAVMs and a Rankin score less than two.3

RESULTS
The trial started on April 4, 2007 and
ended on April 15, 2013 after following 223
patients for 33 months on average. Both
groups had very similar demographics,
clinical symptoms, lesion characteristics
and modified Rankin scores, with the
exception of the interventional therapy
group having a slightly higher proportion of small bAVMs (less than 3 cm).4
The study ended earlier than planned
because it was determined that patients
who received interventional therapy had
a 3-fold increase in their risk of death or
stroke than those who only received pharmacological treatment4. More specifically,
10.1% of patients in the medical management group and 30.7% of patients in the
interventional therapy group reached
the primary endpoint, stroke or death
from any cause during the study. 5 The
primary endpoint incidence rate in the
interventional therapy group was found to
be very similar to the complication rates
of the various invasive procedures when
treating bled and unbled brain AVMs: 29%
for surgery, 25% for embolization, and
13% for radiotherapy. In contrast, medical
management patients had a 2.2% spontaneous rupture rate per year.4
The participants of the ARUBA trial will
continue to be monitored for at least five
more years in order to assess whether
the differences observed in the clinical
outcome and the Rankin scores will
remain the same over time.
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DISCUSSION
Brain AVMs can be detected early on
while they are unruptured and mostly
asymptomatic, but the ideal treatment
is still uncertain. The ARUBA trial argues
that the best treatment for these patients
is solely medical management, using
anticonvulsants if the patient has seizures,
and analgesics if the patient experiences
headaches. However, the ARUBA trial has
received plenty of criticism concerning
its study design and the credibility of its
findings.
The trial states that 30.7% of patients
in the interventional treatment group
reached the primary endpoint, but the
actual symptoms experienced by the
patients are not specified. The primary
endpoint, stroke, is very broadly defined,
including seizure, a new neurological
deficit, or headache that results from
ischemia or hemorrhage.7 There is an
obvious difference in the severity of each
of these clinical presentations, but the
researchers did not identify the likelihood
of each symptom based on which interventional treatment the patient received.7
Moreover, even though the spontaneous
rupture rate per year for patients who
undergo medical management is 2.2%,
the rate increases with increasing age
and patients continue to be at high risk
throughout their lives. The complication
rates of the various interventional treatments are indeed higher, however, the
purpose of interventional therapy is to
obliterate the bAVM so that patients can
avoid increased risk and be worry-free in
the future. Therefore, monitoring patients
for only 33 months is inadequate; patients
need to be monitored for a few decades
in order to assess the risk of hemorrhage throughout their lifespan, as this
is imperative information for making the
right decision by both the doctor and the
patient.6
Furthermore, the vast heterogeneity
in the bAVM morphology and in the
selection of the interventional treatment that the patients received deems
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the generalizability of the trial findings
questionable. First, there is concern that
Mohr et al. introduced selection bias in
the study by studying only relatively mild
cases of bAVMs, because including only
bAVMs without any previous complications is not reflective of the majority
of the cases seen in the hospital. Only
13% (226 out of 1740) of the patients
screened were selected, but the reasons
for excluding the rest were not explicitly
stated.6 If the actual risk of spontaneous
rupture is higher, then conservative
medical management may not be sufficient. Additionally, the effectiveness of
each interventional method varies drastically based on the bAVM morphology.8,9,10
Mohr et al. did not provide enough information concerning the success rate of
each procedure used to treat the different
bAVM types. More details are needed
about the embolic material used in the
embolization procedures, the number
and outcome of patients with total
versus near-total occlusion, and the use
of gamma knife versus linear accelerator
in radiotherapy.7 Lastly, many consider
microsurgical resection of bAVMs to be
more effective than embolization and
radiosurgery in obliterating the nidus, yet
it was used on very few patients. It was the
only treatment used in 5% of the patients
and used in combination with another
procedure in 13% of the patients, but the
reasons behind the preferential use of the
other two methods over microsurgical
resection were not explained.6,7
Due to these limitations in the ARUBA
trial, it is questionable whether we can
group all of the interventional methods
together when assessing their effectiveness in curing bAVMs in comparison to
medical management. More research
needs to be conducted on the long-term
clinical outcome of the two methods of
treatment, taking into consideration the
increased rupture risk with aging and the
varying complication rate of the interventional methods based on the bAVM
morphology.
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